Comparative Pharmacology
Head-to-head clinical analysis: LOCORTEN versus WESTCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCORTEN versus WESTCORT.
LOCORTEN vs WESTCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid